| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 1st March 2021 | Fund V, L.P. Omega | 600 | Open or private sale | $47.12 | $28,272.00 |
| 1st March 2021 | Fund V, L.P. Omega | 3,772 | Open or private sale | $45.49 | $171,588.28 |
| 1st March 2021 | Fund V, L.P. Omega | 2,692 | Open or private sale | $46.28 | $124,585.76 |
| 26th February 2021 | Fund V, L.P. Omega | 2,376 | Open or private sale | $32.87 | $78,099.12 |
| 26th February 2021 | Fund V, L.P. Omega | 5,458 | Open or private sale | $34.28 | $187,100.24 |
| 26th February 2021 | Fund V, L.P. Omega | 3,604 | Open or private sale | $35.93 | $129,491.72 |
| 26th February 2021 | Fund V, L.P. Omega | 7,808 | Open or private sale | $35.27 | $275,388.16 |
| 25th February 2021 | Fund V, L.P. Omega | 242 | Open or private sale | $35.32 | $8,547.44 |
| 25th February 2021 | Fund V, L.P. Omega | 2,013 | Open or private sale | $34.39 | $69,227.07 |
| 25th February 2021 | Fund V, L.P. Omega | 7,424 | Open or private sale | $33.46 | $248,407.04 |
Trevi Therapeutics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease.
Ticker: TRVI
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1563880
Employees: 15
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
